vs
Side-by-side financial comparison of Applied Digital Corp. (APLD) and Pacira BioSciences, Inc. (PCRX). Click either name above to swap in a different company.
Pacira BioSciences, Inc. is the larger business by last-quarter revenue ($177.4M vs $126.6M, roughly 1.4× Applied Digital Corp.). Pacira BioSciences, Inc. runs the higher net margin — 1.6% vs -11.4%, a 13.1% gap on every dollar of revenue. On growth, Applied Digital Corp. posted the faster year-over-year revenue change (98.2% vs 5.0%). Over the past eight quarters, Applied Digital Corp.'s revenue compounded faster (70.9% CAGR vs -0.2%).
BAE Systems Digital Intelligence is an international defence and security technology firm owned by BAE Systems. They specialize in delivering digital solutions that enable rapid, data-driven decision-making. Their services, solutions and products span customers in Law Enforcement, National Security, Government Departments and Government Enterprises, Critical National Infrastructure, Telecommunications, the Military, and Space.
Pacira BioSciences, Inc. is a specialty pharmaceutical company focused on developing and commercializing non-opioid pain management solutions. Its core product line targets post-surgical pain relief for patients, serving hospitals, ambulatory surgery centers and other healthcare providers primarily in the U.S., with ongoing expansion efforts in select international markets.
APLD vs PCRX — Head-to-Head
Income Statement — Q2 FY2026 vs Q1 FY2026
| Metric | | |
|---|---|---|
| Revenue | $126.6M | $177.4M |
| Net Profit | $-14.4M | $2.9M |
| Gross Margin | 20.6% | — |
| Operating Margin | -24.5% | 3.9% |
| Net Margin | -11.4% | 1.6% |
| Revenue YoY | 98.2% | 5.0% |
| Net Profit YoY | 89.6% | — |
| EPS (diluted) | $-0.07 | $0.07 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q1 26 | — | $177.4M | ||
| Q4 25 | $126.6M | $196.9M | ||
| Q3 25 | $64.2M | $179.5M | ||
| Q2 25 | $-33.3M | $181.1M | ||
| Q1 25 | $52.9M | $168.9M | ||
| Q4 24 | $63.9M | $187.3M | ||
| Q3 24 | $60.7M | $168.6M | ||
| Q2 24 | $43.7M | $178.0M |
| Q1 26 | — | $2.9M | ||
| Q4 25 | $-14.4M | — | ||
| Q3 25 | $-16.9M | $5.4M | ||
| Q2 25 | $-52.5M | $-4.8M | ||
| Q1 25 | $-35.6M | $4.8M | ||
| Q4 24 | $-138.7M | — | ||
| Q3 24 | $-4.2M | $-143.5M | ||
| Q2 24 | $-64.5M | $18.9M |
| Q1 26 | — | — | ||
| Q4 25 | 20.6% | 79.5% | ||
| Q3 25 | 13.4% | 80.9% | ||
| Q2 25 | — | 77.4% | ||
| Q1 25 | 7.1% | 79.7% | ||
| Q4 24 | 18.0% | 78.7% | ||
| Q3 24 | -0.6% | 76.9% | ||
| Q2 24 | -9.1% | 75.1% |
| Q1 26 | — | 3.9% | ||
| Q4 25 | -24.5% | 1.2% | ||
| Q3 25 | -34.7% | 3.5% | ||
| Q2 25 | — | 4.7% | ||
| Q1 25 | -35.8% | 1.2% | ||
| Q4 24 | -29.1% | 13.2% | ||
| Q3 24 | 15.6% | -82.8% | ||
| Q2 24 | -68.4% | 15.9% |
| Q1 26 | — | 1.6% | ||
| Q4 25 | -11.4% | — | ||
| Q3 25 | -26.4% | 3.0% | ||
| Q2 25 | 157.8% | -2.7% | ||
| Q1 25 | -67.2% | 2.8% | ||
| Q4 24 | -217.2% | — | ||
| Q3 24 | -7.0% | -85.1% | ||
| Q2 24 | -147.5% | 10.6% |
| Q1 26 | — | $0.07 | ||
| Q4 25 | $-0.07 | $0.05 | ||
| Q3 25 | $-0.07 | $0.12 | ||
| Q2 25 | $-0.31 | $-0.11 | ||
| Q1 25 | $-0.16 | $0.10 | ||
| Q4 24 | $-0.66 | $0.38 | ||
| Q3 24 | $-0.03 | $-3.11 | ||
| Q2 24 | $-0.57 | $0.39 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $1.9B | $144.3M |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $1.4B | $653.9M |
| Total Assets | $5.2B | $1.2B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | $144.3M | ||
| Q4 25 | $1.9B | $238.4M | ||
| Q3 25 | $73.9M | $246.3M | ||
| Q2 25 | $41.6M | $445.9M | ||
| Q1 25 | $68.7M | $493.6M | ||
| Q4 24 | $286.2M | $484.6M | ||
| Q3 24 | $58.2M | $453.8M | ||
| Q2 24 | $3.3M | $404.2M |
| Q1 26 | — | — | ||
| Q4 25 | — | $372.2M | ||
| Q3 25 | — | $376.7M | ||
| Q2 25 | — | $580.5M | ||
| Q1 25 | — | $583.4M | ||
| Q4 24 | — | $585.3M | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
| Q1 26 | — | $653.9M | ||
| Q4 25 | $1.4B | $693.1M | ||
| Q3 25 | $1.0B | $727.2M | ||
| Q2 25 | $497.7M | $757.8M | ||
| Q1 25 | $454.6M | $798.5M | ||
| Q4 24 | $434.6M | $778.3M | ||
| Q3 24 | $241.8M | $749.6M | ||
| Q2 24 | $124.8M | $879.3M |
| Q1 26 | — | $1.2B | ||
| Q4 25 | $5.2B | $1.3B | ||
| Q3 25 | $2.4B | $1.3B | ||
| Q2 25 | $1.9B | $1.5B | ||
| Q1 25 | $1.7B | $1.6B | ||
| Q4 24 | $1.5B | $1.6B | ||
| Q3 24 | $937.7M | $1.5B | ||
| Q2 24 | $762.9M | $1.6B |
| Q1 26 | — | — | ||
| Q4 25 | — | 0.54× | ||
| Q3 25 | — | 0.52× | ||
| Q2 25 | — | 0.77× | ||
| Q1 25 | — | 0.73× | ||
| Q4 24 | — | 0.75× | ||
| Q3 24 | — | — | ||
| Q2 24 | — | — |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $-15.8M | — |
| Free Cash FlowOCF − Capex | $-567.9M | — |
| FCF MarginFCF / Revenue | -448.6% | — |
| Capex IntensityCapex / Revenue | 436.1% | — |
| Cash ConversionOCF / Net Profit | — | — |
| TTM Free Cash FlowTrailing 4 quarters | $-1.3B | — |
8-quarter trend — quarters aligned by calendar period.
| Q1 26 | — | — | ||
| Q4 25 | $-15.8M | $43.7M | ||
| Q3 25 | $-82.0M | $60.8M | ||
| Q2 25 | $6.9M | $12.0M | ||
| Q1 25 | $5.9M | $35.5M | ||
| Q4 24 | $-52.3M | $33.1M | ||
| Q3 24 | $-75.9M | $53.9M | ||
| Q2 24 | $-34.1M | $53.2M |
| Q1 26 | — | — | ||
| Q4 25 | $-567.9M | $43.5M | ||
| Q3 25 | $-331.4M | $57.0M | ||
| Q2 25 | $-191.4M | $9.3M | ||
| Q1 25 | $-251.6M | $26.9M | ||
| Q4 24 | $-223.3M | $31.0M | ||
| Q3 24 | $-130.7M | $49.8M | ||
| Q2 24 | $-88.9M | $51.6M |
| Q1 26 | — | — | ||
| Q4 25 | -448.6% | 22.1% | ||
| Q3 25 | -516.1% | 31.7% | ||
| Q2 25 | 574.8% | 5.1% | ||
| Q1 25 | -475.4% | 15.9% | ||
| Q4 24 | -349.6% | 16.6% | ||
| Q3 24 | -215.3% | 29.6% | ||
| Q2 24 | -203.5% | 29.0% |
| Q1 26 | — | — | ||
| Q4 25 | 436.1% | 0.1% | ||
| Q3 25 | 388.4% | 2.2% | ||
| Q2 25 | -595.4% | 1.5% | ||
| Q1 25 | 486.6% | 5.1% | ||
| Q4 24 | 267.8% | 1.1% | ||
| Q3 24 | 90.3% | 2.4% | ||
| Q2 24 | 125.4% | 0.9% |
| Q1 26 | — | — | ||
| Q4 25 | — | — | ||
| Q3 25 | — | 11.20× | ||
| Q2 25 | — | — | ||
| Q1 25 | — | 7.37× | ||
| Q4 24 | — | — | ||
| Q3 24 | — | — | ||
| Q2 24 | — | 2.82× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
APLD
| HPC Hosting Business | $85.0M | 67% |
| Data Center Hosting Business | $41.6M | 33% |
PCRX
| EXPAREL | $143.3M | 81% |
| ZILRETTA | $26.8M | 15% |
| iovera° | $6.2M | 3% |
| Bupivacaine liposome injectable suspension | $1.2M | 1% |
